HIGHLIGHTS
- who: Qitao Gou and collaborators from the Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Youyi Road, Yuzhong, Chongqing, China have published the paper: Precious Gene: The Application of RET-Altered Inhibitors, in the Journal: Molecules 2022, 8839 of 10/03/2021
- what: This study demonstrated that cabozantinib is active in patients with advanced RET-rearranged lung cancers, with an overall response rate of 28%.
- future: In the future researchers should focus on solving the problem of drug resistance and side effects.
SUMMARY
In the past . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.